CorWave has completed a successful preclinical in vivo study of its implantable heart pump, a left ventricular assist device (LVAD) utilizing innovative wave membrane technology. The device, which operates in pulsatile mode and adapts to the patient’s activity level, was shown to function for six months without failure, with no signs of thrombosis at explant.
The study’s positive results, which included nine chronic ovine implants over 60 days without anticoagulant therapy, mark the final stage of preclinical development for CorWave. The company is now preparing for a first-in-human trial. Experts believe the device could offer significant clinical advantages over traditional rotary blood pumps used for mechanical circulatory support.
Follow MEDWIRE.AI for updates on cutting-edge heart pump technologies.
